Leukemia: Comparison of survival outcomes in autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL

Mature T-cell lymphoma (TCL) is a heterogeneous subgroup of non-Hodgkin lymphoma (NHL) with a relatively poor prognosis compared with B-cell NHL

Mature T-cell lymphoma (TCL) is a heterogeneous subgroup of non-Hodgkin lymphoma (NHL) with a relatively poor prognosis compared with B-cell NHL

Patients with relapsed or refractory (R/R) disease have a very poor prognosis (median overall survival [OS] < 6 months)

Therefore, the aim of a nationwide retrospective study was to compare the effects of autologous and allogeneic HCT in relapsed or refractory TCL

Figure 1: Comparison of overall survival (OS) and relapse/progression-free survival (PFS) between autologous and allogeneic hematopoietic stem cell transplantation

Figure 1: Comparison of overall survival (OS) and relapse/progression-free survival (PFS) between autologous and allogeneic hematopoietic stem cell transplantation

Of these, 318 were relapse after first remission (REL) and 442 were refractory to primary therapy (PIF)

Of these, 318 were relapse after first remission (REL) and 442 were refractory to primary therapy (PIF)

Figure 2: Comparison of recurrence/progression incidence (RI) and non-relapse/progression mortality (NRM) between autologous liver transplantation and allogeneic HCT

Figure 2: Comparison of recurrence/progression incidence (RI) and non-relapse/progression mortality (NRM) between autologous liver transplantation and allogeneic HCT

In multivariate analysis, alloHCT tended to be associated with better progression-free survival (PFS) in REL ([HR] 0.

In multivariate analysis, alloHCT tended to be associated with better progression-free survival (PFS) in REL ([HR] 0.

Figure 3: Comparison of overall survival between allogeneic HCT and autologous HCT based on patient characteristics of REL group (A) and PIF group (B).

Figure 3: Comparison of overall survival between allogeneic HCT and autologous HCT based on patient characteristics of REL group (A) and PIF group (B).

Propensity-score-matched subgroup analyses indicated that alloHCT was associated with better OS in REL-sensitive and PIF-non-remitting disease

Figure 4: Survival comparison of autologous and allogeneic hct in propensity score-matched cohorts

Figure 4: Survival comparison of autologous and allogeneic hct in propensity score-matched cohort Figure 4: Survival comparison of autologous and allogeneic hct in propensity score-matched cohort

In conclusion, the survival outcomes of allogeneic HCT for relapsed or refractory PTCL-NOS or AITL were comparable to autologous HCT

relapsed or refractory

 

Original source:

Original source:

Kameda, K.

Kameda, K.
, Kako, S.
, Kim, SW.
  et al.
 Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
  Leukemia (2022).
https://doi.
org/10.
1038/s41375- 022-01545-w.
et al.
Leukemia

leave a message here